Revenue: As of FY2025 Q2, the actual value is USD 13.24 M.EPS: As of FY2025 Q2, the actual value is USD -0.07.EBIT: As of FY2025 Q2, the actual value is USD -1.829 M.<h3>Segment Revenue</h3><ul><li>Consolidated Revenue: $13.2 million for the quarter ended June 30, 2025, compared to $17.0 million for the quarter ended June 30, 2024. The decrease was primarily driven by a decline in Healthcare Operations.</li><li>Pharmacy Prescription and Other Revenue: $8.2 million for the quarter ended June 30, 2025, compared to $10.5 million in the prior year quarter.</li><li>Pharmacy 340B Contract Revenue: $1.0 million for the quarter ended June 30, 2025, compared to $3.0 million in the prior year quarter.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit Margin: Overall gross profit margin declined to 21.8% from 34.5% in the prior year quarter. Gross profit margin for Healthcare segment decreased to 19.9% from 35.2%, and for e-Commerce Operations decreased to 25.9% from 31.6%.</li><li>Operating Expenses: Decreased to $4.7 million for the quarter ended June 30, 2025, compared to $16.8 million in the prior year quarter. The prior year included $9.7 million in non-recurring expenses.</li><li>Net Loss: Net loss attributable to NextPlat Corp common shareholders decreased 66% to $1.8 million, or - $0.07 per diluted share, compared to a net loss of $5.3 million, or - $0.28 diluted earnings per share in the prior year quarter.</li></ul><h3>Cash Flow</h3><ul><li>Cash: The company ended the quarter with $16.6 million in cash.</li></ul><h3>Unique Metrics</h3><ul><li>e-Commerce Revenue Growth: Driven by record levels of recurring airtime contracts and elevated hardware sales. The company continues to see near-term growth opportunities in this segment.</li><li>OPKO Healthcare Products: Continued growth in sales on Alibaba’s Tmall Global in China despite limited permissible inventory levels. The company is working to secure increased inventory volumes and awaits regulatory approval to introduce OPKO pet health products.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company expects the positive impact of cost-reduction and business process improvements in Healthcare Operations to contribute to operational results throughout the remainder of 2025 and into 2026.</li><li>The company has identified three primary objectives: continued operational process efficiency and cost reduction efforts, ensuring necessary talent is leading the business, and renewing a commitment to prudently invest in the business to capitalize on opportunities.</li><li>Significant developments against these objectives are expected to be announced over the next 60 days.</li></ul>

NEXTPLAT CORP C/WTS 02/06/2027 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 13.24 M